Pomerantz LLP opens investor investigation into Celcuity Inc., joining a series of similar alerts across multiple industries

Pomerantz LLP announced an investigation into claims on behalf of investors of Celcuity Inc. (NASDAQ: CELC) regarding possible securities law violations. The probe could result in a class action lawsuit, exposing Celcuity to legal expenses and share price volatility, while highlighting a broader trend of plaintiff law firm scrutiny across sectors. Who is involved: Pomerantz LLP, lead attorney Danielle Peyton, Celcuity Inc., and its shareholders.. Likely next: Investors may be contacted to join the investigation; if sufficient claims are collected, a formal class action complaint could be filed in the coming weeks.. On July 16 2026, the law firm Pomerantz LLP disclosed that it had opened an investor‑focused investigation into possible claims against Celcuity Inc. (CELC). The announcement was part of a batch of similar notices issued the same day for other publicly traded companies, including Wix.com Ltd. (WIX), HCA Healthcare, Inc. (HCA) and International Business Machines Corporation (IBM). In each case the firm stressed that the notices do not constitute allegations of misconduct; rather, they indicate that Pomerantz is collecting information from shareholders that could support a future class‑action complaint. Such inquiries are a preliminary step in securities litigation. Law firms typically solicit shareholder input to determine whether there are sufficient grounds to file a formal complaint, a process that can take weeks or months. While no wrongdoing has been asserted, the mere existence of an investigation can prompt companies to allocate resources to legal review and may influence how investors assess risk. Historically, when multiple firms are targeted in a short period, market participants sometimes react to the heightened legal uncertainty, which can affect trading volume and, over time, contribute to higher defense costs. The ultimate outcome of the Pomerantz inquiries remains uncertain, and any further developments will depend on the evidence gathered and the decisions of the plaintiffs’ counsel. Sectors affected: biotechnology diagnostics Regulatory implications: Potential SEC review of Celcuity's disclosures

Geographic Focus

Executive Summary

✦ Editor's Take · Objective

Timeline

Relationship Graph

Live Feed

Source Evidence

AI Insights

Entities

Social Pulse